CDK2-IN-9

• Description:

  CDK2-IN-9 is a potent CDK2 inhibitor with an IC50 of 0.63 μM. CDK2-IN-9 shows antiproliferative activity. CDK2-IN-9 induces apoptosis and cell cycle arrest at S and G2/M phase. CDK2-IN-9 has the potential for the research of melanoma[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; CDK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cdk2-in-9.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=S(C1=CC=C(Cl)C=C1)(NN2C(COC3=CC=CC=C3)=NC4=C(C=CC=C4)C2=O)=O

• Molecular Formula:

  C21H16ClN3O4S

• Molecular Weight:

  441.89

• References & Citations:

  [1]Mohammed ER, et al. Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma. J Enzyme Inhib Med Chem. 2022 Dec;37 (1) :686-700.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK2

• CAS Number:

  [2919216-33-2]